FAP靶向单域抗体4AH29与肽FAP-2286的头对头临床前比较
该临床前研究在相关啮齿类肿瘤模型中头对头比较了放射性标记的FAP靶向单域抗体4AH29与肽FAP-2286的体外和体内肿瘤滞留、剂量学及疗效。结果显示[177Lu]Lu-DOTA-4AH29在U87-MG和HT-29模型中肿瘤滞留优于FAP-2286,肿瘤吸收剂量分别高3倍和2倍,且[225Ac]Ac-DOTA-4AH29可改善生存,提示4AH29具有更优抗肿瘤潜力。
要点
- 体外[177Lu]Lu-DOTA-4AH29细胞相关活性持续至48小时,而FAP-2286在最初数小时内降至基线。
- U87-MG模型中[177Lu]Lu-DOTA-4AH29的肿瘤吸收剂量为FAP-2286的3倍,HT-29中为2倍。
- [225Ac]Ac-DOTA-4AH29较[177Lu]Lu-DOTA-FAP-2286改善生存,支持进一步临床研究。
核心结论
- 临床前结果提示放射性标记4AH29因增强的肿瘤滞留和更明显的抗肿瘤效应,较FAP-2286具有潜在优势,值得临床研究。
研究设计与样本
- 在相关啮齿类肿瘤模型(U87-MG、HT-29、HEK-hFAP)中头对头比较放射性标记的FAP靶向单域抗体4AH29与肽FAP-2286的体外和体内肿瘤滞留、剂量学及疗效。
主要发现
- 体外[177Lu]Lu-DOTA-4AH29细胞相关活性持续至48小时,而[177Lu]Lu-DOTA-FAP-2286在最初数小时内降至基线。
- U87-MG模型中[177Lu]Lu-DOTA-FAP-2286早期肿瘤聚集更好,但24小时后滞留显著低于[177Lu]Lu-DOTA-4AH29,后者肿瘤吸收剂量高3倍。
- HT-29模型中两种示踪剂绝对肿瘤摄取均低于U87-MG,与较低FAP表达一致,[177Lu]Lu-DOTA-4AH29肿瘤滞留随时间显著改善,肿瘤吸收剂量高2倍。
- HEK-hFAP模型中[177Lu]Lu-DOTA-FAP-2286在所有评估时间点肿瘤摄取增强,肿瘤吸收剂量较[177Lu]Lu-DOTA-4AH29高4.8倍。
- 接种后43天,[177Lu]Lu-DOTA-4AH29或[225Ac]Ac-DOTA-4AH29较[177Lu]Lu-DOTA-FAP-2286显著延迟U87-MG肿瘤发展;[225Ac]Ac-DOTA-4AH29改善生存,[177Lu]Lu-DOTA-4AH29呈趋势。
关键数值与推荐
- U87-MG模型中[177Lu]Lu-DOTA-4AH29肿瘤吸收剂量为[177Lu]Lu-DOTA-FAP-2286的3倍。
- HT-29模型中[177Lu]Lu-DOTA-4AH29肿瘤吸收剂量为[177Lu]Lu-DOTA-FAP-2286的2倍。
- HEK-hFAP模型中[177Lu]Lu-DOTA-FAP-2286肿瘤吸收剂量较[177Lu]Lu-DOTA-4AH29高4.8倍。
- HT-29模型中单次注射120 kBq [225Ac]Ac-DOTA-4AH29获得生存改善。
临床怎么用
- 临床前数据支持4AH29作为FAP靶向放射性配体治疗候选分子进一步开展临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiolabeled FAP-targeting sdAb 4AH29 was developed previously, showing potent therapeutic efficacy. This head-to-head study compares sdAb 4AH29 and peptide FAP-2286, generally considered as most clinically advanced, for their in vitro and in vivo tumor retention, resulting dosimetry, and therapeutic efficacy in relevant rodent tumor models. RESULTS: In vitro, [177Lu]Lu-DOTA-4AH29 showed sustained cell-associated activity until 48 h, whereas it dropped to baseline within the first hours for [177Lu]Lu-DOTA-FAP-2286. In vivo, in U87-MG, [177Lu]Lu-DOTA-FAP-2286 accumulated better at the tumor at early time points but from 24 h was significantly less retained than [177Lu]Lu-DOTA-4AH29, leading to a threefold higher absorbed dose to the tumor for [177Lu]Lu-DOTA-4AH29. Compared to U87-MG, absolute tumor uptake for both tracers in HT-29 was decreased, in line with lower FAP expression of this model. Of note, significant improved tumor retention was observed for [177Lu]Lu-DOTA-4AH29 over time, resulting in a twofold higher tumor absorbed dose. The transfected HEK-hFAP model showed an enhanced tumor uptake with [177Lu]Lu-DOTA-FAP-2286 at all assessed time points, displaying a 4.8 more elevated absorbed dose to tumor than [177Lu]Lu-DOTA-4AH29. Treatment with [177Lu]Lu-DOTA-4AH29 or [225Ac]Ac-DOTA-4AH29 significantly delayed U87-MG tumor development compared to [177Lu]Lu-DOTA-FAP-2286 43 days post inoculation. Survival was improved after administration of [225Ac]Ac-DOTA-4AH29 compared to [177Lu]Lu-DOTA-FAP-2286, whereas it was a trend with [177Lu]Lu-DOTA-4AH29. In HT-29, no significant differences in tumor control were observed at day 29 before first animal reached humane endpoint. Nevertheless, enhanced survival was achieved with a single shot of [225Ac]Ac-DOTA-4AH29 at 120 kBq. CONCLUSIONS: These preclinical results underline the potential benefit of radiolabeled 4AH29 over FAP-2286 due to its enhanced tumor retention and more pronounced anti-tumor effects warranting clinical investigation.
引用
- Dumauthioz N, Navarro L, Berdal M, et al. Head-to-head comparison of FAP-targeting single-domain antibody 4AH29 vs. peptide FAP-2286. EJNMMI Res. 2026. PMID: 41688618. doi:10.1186/s13550-026-01392-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。